We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First Mobile Diagnostic System Performs Instant Lab Quality Blood Analysis Anywhere

By LabMedica International staff writers
Posted on 25 Aug 2023

Presently, the complete blood count (CBC) is one of the most frequently recommended diagnostic tests to evaluate an individual's overall health by measuring factors like oxygen-transporting red blood cells, infection-combating white blood cells, and blood-coagulating platelets. More...

However, there are issues with CBC testing such as patient expenses, accessibility, and time consumption. Patients require a referral, followed by scheduling a nurse appointment for blood collection. This is followed by waiting in the clinic, and sometimes waiting for hours or days after the blood draw to obtain the results. Moreover, a substantial portion of the global population lacks access to proper diagnostics due to distance from clinics or financial constraints. Now, a groundbreaking diagnostic system is making waves in the point of care (POC) setting, offering the first mobile technology for instant blood analysis beyond the confines of a lab. This innovation has the potential to bring lab tests within reach of millions worldwide.

The REVDX from EFA Technologies (Caesarea, Israel) is a portable lab-quality device that incorporates advanced multi-channel technology. This handheld device can be used anywhere, eliminating the need for time-consuming preparations or specialized knowledge. It is mobile, portable, and handheld, capable of functioning without electricity or internet connectivity, while also being cost-effective. At present, the device can conduct a blood count, with plans for additional tests in the future. A simple finger prick is all that's required, eliminating the need to visit a lab and delivering results in just minutes. The device aims to empower doctors and medical teams in diverse scenarios to make informed treatment decisions promptly, bypassing the wait time for blood tests and their subsequent results. The REVDX is user-friendly, operating via a finger prick and independent of elaborate lab conditions or specific preparations.

In patients with fever, the most critical test to conduct is a CBC. These results can assist in administering antibiotics for suspected bacterial infections, avoiding unwarranted antibiotic use in viral infections, and identifying parasitic infections like malaria. Presently, most labs provide CBC results within 24 to 72 hours, with a significant time lapse during test transportation. The absence of real-time blood count data contributes to antibiotic overuse, which exacerbates antimicrobial resistance (AMR). REVDX has the capability to conduct automated microscopy tests, encompassing full blood sampling and immediate full blood count diagnosis. Physicians can utilize REVDX to make real-time, informed judgments about the likelihood of a bacterial infection, curtailing unnecessary antibiotic use. This positions REVDX as an indispensable device for every point of need across the world.

Related Links:
EFA Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.